Norges Bank Prothena Corp Public LTD CO Transaction History

Norges Bank

$716 Trillion
Q3 2024

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $1.12 Million - $1.5 Million	57,454 New	57,454 $1.19 Million
Q4 2023 Feb 09, 2024	BUY	$32.31 - $52.32 $3.38 Million - $5.47 Million	104,564 New	104,564 $3.8 Million
Q3 2023 Nov 13, 2024	BUY	$47.3 - $70.6 $4.95 Million - $7.38 Million	104,564 New	104,564 $5.05 Million
Q3 2023 Nov 13, 2023	SELL	$47.3 - $70.6 $1.67 Million - $2.5 Million	-35,400 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$48.26 - $78.59 $2.27 Million - $3.7 Million	47,110 Added 82.0%	104,564 $7.14 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $3.71 Million - $6.04 Million	-76,800 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$46.97 - $58.27 $10.3 Million - $12.8 Million	218,814 New	218,814 $10.6 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $3.08 Million - $3.85 Million	59,259 New	59,259 $3.57 Million
Q3 2022 Nov 13, 2023	BUY	$25.16 - $60.63 $890,664 - $2.15 Million	35,400 New	35,400 $2.15 Million
Q2 2022 Aug 14, 2023	BUY	$22.73 - $39.98 $1.75 Million - $3.07 Million	76,800 New	76,800 $2.09 Million
Q1 2022 May 12, 2023	BUY	$30.27 - $49.22 $530,966 - $863,368	17,541 Added 29.6%	76,800 $2.81 Million
Q1 2022 May 09, 2022	SELL	$30.27 - $49.22 $2.32 Million - $3.78 Million	-76,800 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$42.11 - $73.26 $3.23 Million - $5.63 Million	76,800 New	76,800 $3.79 Million
Q3 2019 Nov 08, 2019	SELL	$6.89 - $10.45 $336,094 - $509,750	-48,780 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$8.85 - $12.49 $431,703 - $609,262	48,780 New	48,780 $516,000
Q2 2019 Aug 09, 2019	SELL	$8.85 - $12.49 $1.06 Million - $1.49 Million	-119,553 Closed	0 $0
Q1 2019 May 11, 2020	SELL	$10.32 - $14.49 $982,856 - $1.38 Million	-95,238 Reduced 44.34%	119,553 $1.45 Million
Q4 2018 Mar 04, 2019	BUY	$8.73 - $13.74 $1.88 Million - $2.95 Million	214,791 New	214,791 $2.21 Million
Q4 2018 Feb 08, 2019	SELL	$8.73 - $13.74 $3.29 Million - $5.18 Million	-376,816 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$12.7 - $15.79 $4.79 Million - $5.95 Million	376,816 New	376,816 $4.93 Million
Q3 2018 Nov 09, 2018	SELL	$12.7 - $15.79 $4.79 Million - $5.95 Million	-376,816 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$10.99 - $44.21 $4.14 Million - $16.7 Million	376,816 New	376,816 $5.49 Million
Q2 2018 Jul 23, 2018	SELL	$10.99 - $44.21 $4.14 Million - $16.7 Million	-376,816 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$27.95 - $45.04 $10.5 Million - $17 Million	376,816 New	376,816 $13.8 Million
Q1 2018 May 09, 2018	SELL	$27.95 - $45.04 $9.73 Million - $15.7 Million	-348,016 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$35.44 - $63.76 $12.3 Million - $22.2 Million	348,016 New	348,016 $13 Million
Q4 2017 Feb 09, 2018	SELL	$35.44 - $63.76 $12.3 Million - $22.2 Million	-348,016 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$53.83 - $67.75 $18.7 Million - $23.6 Million	348,016 New	348,016 $22.5 Million
Q3 2017 Nov 07, 2017	SELL	$53.83 - $67.75 $16.7 Million - $21.1 Million	-310,957 Closed	0 $0
Q2 2017 Jul 24, 2018	SELL	N/A	-48,469 Reduced 13.49%	310,957 $16.8 Million
Q1 2017 May 11, 2018	SELL	N/A	-12,127 Reduced 3.26%	359,426 $20.1 Million
Q3 2016 Nov 13, 2017	BUY	N/A	371,553	371,553 $0

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

Eco R1 Capital, LLC San Francisco, CA

11.6M
Shares

$176 Million
8.41% of portfolio
Wellington Management Group LLP Boston, MA

4.18M
Shares

$63.6 Million
0.01% of portfolio
Black Rock Inc. New York, NY

3.86M
Shares

$58.7 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.82M
Shares

$58.2 Million
0.01% of portfolio
Palo Alto Investors LP Palo Alto, CA

1.74M
Shares

$26.5 Million
4.0% of portfolio

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account